bioAffinity TechnologiesBIAF -1.48%44 Return-on-Tangible-Equity is -432.84% as of Mar. 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 96.89% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. bioAffinity Technologies's annualized net income for the quarter that ended in Mar. 2026 was $-14.52 Mil. bioAffinity Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $3.36 Mil. Therefore, bioAffinity Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -432.84%.
The historical rank and industry rank for bioAffinity Technologies's Return-on-Tangible-Equity or its related term are showing as below:
BIAF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -937.98 Med: -534.5 Max: -116.21
Current: -937.98
During the past 6 years, bioAffinity Technologies's highest Return-on-Tangible-Equity was -116.21%. The lowest was -937.98%. And the median was -534.50%.
BIAF's Return-on-Tangible-Equity is ranked worse than 96.89% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs BIAF: -937.98
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
bioAffinity Technologies Return-on-Tangible-Equity Related Terms
bioAffinity Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for bioAffinity Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIAF vs NDRA, ISPC, ADVB: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -432.84% mean?
bioAffinity Technologies (BIAF) has a Return-on-Tangible-Equity of -432.84% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on bioAffinity Technologies and its competitors. According to the industry distribution chart, bioAffinity Technologies ranks #187 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 96.9%.
Is bioAffinity Technologies' Return-on-Tangible-Equity too high?
bioAffinity Technologies' current Return-on-Tangible-Equity is -432.84%. Based on the distribution chart, bioAffinity Technologies ranks #187 out of 193 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Return-on-Tangible-Equity compare to NDRA and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #187 out of 193 companies for Return-on-Tangible-Equity. This places bioAffinity Technologies in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Return-on-Tangible-Equity is -432.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current Return-on-Tangible-Equity is -432.84%. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Return-on-Tangible-Equity is -432.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
Return-on-Tangible-Equity: -432.84%
GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
